Patient
portrayal

Learn about CABOMETYX
What is CABOMETYX?
CABOMETYX is a kind of medication called a tyrosine kinase inhibitor (TKI). It is given as a tablet.
It is used to treat:
- Adults and children 12 years and older with differentiated thyroid cancer (DTC) that has spread (locally advanced or metastatic) and has progressed after a VEGFR-targeted treatment and can no longer be treated with radioactive iodine therapy (RAI), or are unable to receive it.
How CABOMETYX may help
In a clinical study, CABOMETYX was given to people who had differentiated thyroid cancer that had spread and progressed after prior treatment with a TKI medicine (VEGFR-targeted treatment) and could no longer be treated with radioactive iodine (RAI) or not able to receive RAI.
In the first analysis:

125 people took CABOMETYX

62 people took placebo
In the later analysis:

170 people took CABOMETYX

88 people took placebo
Each person's results with CABOMETYX may be different.
The study looked at Progression Free Survival (PFS): how long people live without their cancer growing or spreading.
In the first analysis, people who took CABOMETYX were able to LIVE LONGER without their cancer growing or spreading.
In the first analysis, more than half of people who took CABOMETYX did not see their cancer get worse or spread. Meaning, a study goal known as median progression free survival (PFS)* was not yet reached.
In the first and later analyses, people taking CABOMETYX reduced the risk of their cancer growing or spreading by 78% compared to placebo.
In the later analysis
It was shown that people taking CABOMETYX were able to live longer without their cancer growing or spreading.

- *
-
PFS shows how long people live without their disease growing or spreading. Median PFS is the length of time from the start of treatment in a study that half the people lived without their tumors growing or spreading.
The study also looked at Overall Response Rate (ORR): the number of people who have a response to treatment†

The response was reported in 15% of people who took CABOMETYX compared to none (0%) of the people who took the placebo.
While there was a response rate, it did not reach the goal of the study.‡
Each person’s results with CABOMETYX may be different.

Side Effects
Hear a Patient and Doctor Share Their Perspectives About Side Effects
Thomas Hutson, D.O., Pharm.D., and Rosa, an actual patient, talk about the importance of knowing what to expect with side effects of CABOMETYX.
This video features a real patient and doctor to show one individual’s treatment experience with CABOMETYX. Some participants were paid for their time and expenses in sharing their story. Individual results may vary. The information in this video is not intended as medical advice. Your healthcare team is your best resource for information about your treatment. If you have any questions about your condition or treatment, contact your healthcare team.
What are the most common side effects of CABOMETYX?
Taking CABOMETYX may cause side effects. The most common side effects of CABOMETYX include: tiredness, decreased appetite, nausea and vomiting, weight loss, and constipation.
Learn about additional side effects, including serious side effects associated with CABOMETYX here.
LEARN MORE ABOUT

Patient Brochure
Download this resource to learn more about CABOMETYX, and help you discuss with your doctor if it is right for you.

The BE CONNECTED support program provides educational information for you or someone you are caring for who is taking CABOMETYX.